Physician profile
William W Thoms
NPI 1215087309
$1,191.04
in general payments reported to CMS, 2019-2025
22 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $131 · 2022: $64.21 · 2023: $34.19 · 2024: $41.86 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $113.66 | 2025 | Tagrisso |
| Tesaro, INC. | $99.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.48 | 2019 | |
| Boston Scientific Corporation | $95.03 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $87.57 | 2019 | |
| Seagen INC. | $86.69 | 2019 | |
| Pfizer INC. | $81.12 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $68.42 | 2025 | Orgovyx |
| Fortovia Therapeutics, INC. | $61.68 | 2019 | |
| Novocure INC. | $57.73 | 2019-2022 | |
| Tersera Therapeutics LLC | $54.89 | 2025 | Zoladex |
| Merck Sharp & Dohme LLC | $52.85 | 2025 | Keytruda |
| Genzyme Corporation | $30.58 | 2023-2024 | |
| Siemens Medical Solutions USA, INC. | $28.62 | 2022 | |
| Coherus Oncology, INC. | $26.29 | 2025 | Loqtorzi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $25.74 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $22.38 | 2025 | Iclusig |
| Eisai INC. | $22.10 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.61 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.73 | 2023 | Onivyde |
| Beone Medicines USA, INC. | $17.92 | 2025 | Tevimbra |
| Myriad Genetic Laboratories, INC. | $17.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thoms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.